<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01471925</url>
  </required_header>
  <id_info>
    <org_study_id>EF 095</org_study_id>
    <nct_id>NCT01471925</nct_id>
  </id_info>
  <brief_title>Study Comparing Esomeprazole Associated With Sodium Bicarbonate From Eurofarma and Esomeprazole in Treatment of Gastroesophageal Reflux Disease ESOBIC</brief_title>
  <official_title>A Phase III, Randomized, Open-label, Superiority Study Comparing the Incremental Product Esomeprazole Associated With Sodium Bicarbonate Made by Eurofarma and Nexium® in the Treatment of Gastroesophageal Reflux Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eurofarma Laboratorios S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eurofarma Laboratorios S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase III, randomized, open-label, superiority study comparing the incremental product
      esomeprazole associated with sodium bicarbonate made by Eurofarma and Nexium® in the
      treatment of gastroesophageal reflux disease. The study will enroll 94 patients in each arm
      (total of 188 patients).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Change company strategy
  </why_stopped>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>1 month</time_frame>
    <description>Primary efficacy analysis the value for intragastric pH 10 centimeters distant from the lower esophageal sphincter and the pH value 1 hour after using study medication during randomization visit will be considered for primary study assessment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Esomeprazole (40mg) + Sodium Bicarbonate (721mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nexium®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nexium®</intervention_name>
    <arm_group_label>Nexium®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazol (40mg) + Sdium Bicarbonate (721mg)</intervention_name>
    <arm_group_label>Esomeprazole (40mg) + Sodium Bicarbonate (721mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        ICF signing;

          -  Age ≥ 18 years;

          -  Gastroesophageal reflux disease diagnosis;

          -  Grade 0 to grade III reflux esophagitis, assessed by means of upper gastrointestinal
             endoscopy;

          -  Ability to have the endoscopy, pH-metry and esophageal manometry examinations
             performed;

          -  Washout period of 1 week without using PPI, H2 antagonists and prokinetic agents and
             of at least 1 day without using antacids.

        Exclusion Criteria:

          -  Presence of esophagitis requiring intervention (grade IV), esophageal varices,
             Barrett's esophagus, systemic sclerosis or ulcers (gastric or duodenal ulcers);

          -  Previous gastric or esophageal surgery;

          -  Dietary sodium restriction, metabolic alkalosis, hypokalemia, Barter syndrome;
             Pregnancy or breastfeeding;

          -  Concomitant diseases, such as kidney, liver and heart failure;

          -  Suspected or confirmed cancer of any type;

          -  Abusive drug or alcohol use;

          -  Abnormal values for white blood cells, platelets or hemoglobin;

          -  Significant changes in serum sodium, potassium, calcium or creatinine concentrations;

          -  Treatment with PPI, H2 antagonists or prokinetic agents that may not be withheld
             during the washout period of 1 week or during the study;

          -  Intolerance or allergy to any of the components in the drug products assessed in the
             study;

          -  Use of nonsteroidal anti-inflammatory drugs (NSAIDs), antiemetic agents, macrolide
             antibiotics and systemic corticoids for a period equal to or greater than 2 weeks
             before the study or that is expected to require prolonged use during study treatment;

          -  Concomitant use or requirement of a gastric pH-dependent medication for optimal
             absorption;

          -  Scheduled use of other medications metabolized by cytochrome CYP during the study;

          -  History of active peptic ulcer;

          -  Rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or
             sucrose-isomaltase insufficiency;

          -  Recent participation (within the last 12 months) in another clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto Goiano de Gastroenterologia</name>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mãe de Deus Center</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de pesquisa Clínica do Serviço de gastroenterologia</name>
      <address>
        <city>Rio de janeiro</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Israelita Albert Einstein</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Clínica de Campinas</name>
      <address>
        <city>Canpinas</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos Clínicos do Interior Paulista</name>
      <address>
        <city>Jaú</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2011</study_first_submitted>
  <study_first_submitted_qc>November 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2011</study_first_posted>
  <last_update_submitted>July 24, 2015</last_update_submitted>
  <last_update_submitted_qc>July 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

